Bank of America Merrill Lynch Form 38.5 (a) - Allergan (3484D)

TIDM0Y7T

RNS Number : 3484D

Bank of America Merrill Lynch

18 February 2020

FORM 38.5(a)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED

INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 
1.  KEY INFORMATION 
 
 
 Name of exempt principal trader:            Merrill Lynch International 
 Company dealt in                            Allergan PLC 
                                            ---------------------------- 
 Class of relevant security to which the     Common - IE00BY9D5467 
   dealings being disclosed relate(Note 1) 
                                            ---------------------------- 
 Date of dealing                             17/02/2020 
                                            ---------------------------- 
 
 
2.  DEALINGS (Note 2) 
 
 
(a)  Purchases and sales 
 
 
Total number of relevant securities acquired  Highest price paid (Note 3)  Lowest price paid (Note 3) 
N/A                                           N/A                          N/A 
                                              ---------------------------  -------------------------- 
 
 
 Total number of securities disposed   Highest price received (Note 3)   Lowest price received (Note 3) 
 N/A                                   N/A                               N/A 
                                      --------------------------------  ------------------------------- 
 
 
(b)  Derivatives transactions (other than options transactions) 
 
 
 Product name,   Nature of transaction   Number of relevant securities   Price per unit 
  e.g. CFD        (Note 4)                (Note 5)                        (Note 3) 
      N/A                 N/A                         N/A                     N/A 
                ----------------------  ------------------------------  --------------- 
 
 
(c)  Options transactions in respect of existing relevant 
      securities 
 
 
(i)  Writing, selling, purchasing or varying 
 
 
  Product       Writing,       Number of      Exercise        Type,        Expiry date    Option money paid/ received 
    name,       selling,       securities       price     e.g. American,                       per unit (Note 3) 
  e.g. call    purchasing,      to which                     European 
   option        varying       the option                      etc 
                  etc.        relates (Note 
                                   5) 
    N/A           N/A             N/A           N/A            N/A             N/A                    N/A 
             -------------  ---------------  ---------  ----------------  ------------  ------------------------------ 
 
 
(ii)  Exercising 
 
 
  Product name,        Number of securities    Exercise price per 
   e.g. call option                             unit (Note 3) 
        N/A                    N/A                    N/A 
                     ----------------------  -------------------- 
 
 
3.  OTHER INFORMATION 
 
 
Agreements, arrangements or understandings relating 
 to options or derivatives 
 
 
 Full details of any agreement, arrangement or understanding between the person 
  disclosing and any other person relating to the voting rights of any relevant 
  securities under any option referred to on this form or relating to the voting rights 
  or future acquisition or disposal of any relevant securities to which any derivative 
  referred to on this form is referenced. If none, this should be stated. 
 35 shares returned 
 42 shares returned 
 
 
 
 Date of disclosure              18/02/2020 
 Contact name                    Tolu Tade 
                                ------------------------ 
 Telephone number                [phone] 
                                ------------------------ 
 Name of offeree/offerer with    AbbVie Inc 
  which connected 
                                ------------------------ 
 Nature of connection(Note 6)    Advisor to - AbbVie Inc 
                                ------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ISESFSFSAESSEDE

(END) Dow Jones Newswires

February 18, 2020 05:33 ET (10:33 GMT)